Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer

Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00858520

Enrollment

2000

Registered

2009-03-10

Start date

2007-10-31

Completion date

2019-12-31

Last updated

2013-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Lung Cancer

Keywords

COPD, Lung cancer, genes, DNA

Brief summary

A biobank of Serum, plasma, DNA samples together with clinical information including specific questionnaires, complete pulmonary function and chest CT-scan, is prospectively collected in patients seen at the investigators' clinical service. The objective is to study candidate gene pathways in COPD and or lung cancer and to associate them with the clinical characteristics and phenotypes of COPD/emphysema and lung cancer. In subgroups of well characterised patients, other biological materials are also collected (lung tissue biopsies, peripheral blood mononuclear cells).

Detailed description

All patients with a smoking history of at least 15 pack years, an minimal age of 50 years and an recent available CT scan are enrolled. All subjects with a diagnosis of lung cancer are also collected (irrespective of age and smoking behavior). In addition the investigators collect: * specific questionnaires (MRC, CCQ and smoking history) * medical and professional history * complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity) * serum, plasma and DNA samples. In specific subgroups the investigators also collect: * Peripheral blood mononuclear cells * Lung tissue - if available - from a surgical procedure (lung transplantation or lobectomy)

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

for smokers: * A smoking history of at least 15 pack years and age of 50 years or older * Complete pulmonary function on day of visit * Chest CT-scan within one year of enrollment * 4 weeks from exacerbation

Exclusion criteria

for smokers: * Less than 15 pack years * Younger than 50 year * Other pulmonary diseases interfering with CT or pulmonary function * Asthma Inclusion Criteria for lung cancer patients: * new diagnosis of proven lung cancer * chest CT scan within 2 months of enrollment * Complete pulmonary function

Design outcomes

Primary

Measure	Time frame	Description
Serological, cytological, histological and genetic analysis of biomarkers or genes which are involved in the pathogenesis of COPD/Emphysema/Lungcancer.	0-1-3-6 years	All cases are prospectively collected in University hospital Leuven, Belgium. Of enrolled subjects data are collected at 0,1,3 and 6 years interval

Countries

Belgium

Contacts

Primary ContactWim Janssens, MD. PhD.

wim.janssens@uz.kuleuven.ac.be032 (16) 34 68 00

Backup ContactKristien Debent

kristien.debent@uz.kuleuven.ac.be032 (16) 34 31 26

Outcome results